Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Joshi S, Durden DL. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J Oncol. 2019;2019:1–18.
   Web of Science ®Google Scholar
• Klener P, Jr., Otahal P, Lateckova L, Klener P. Immunotherapy approaches in cancer treatment. CPB. 2015;16(9):771–81.
   Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280(1):126–48. Nov
   PubMed Web of Science ®Google Scholar
• Serrano D, Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol. 2019;7:50.
   PubMed Web of Science ®Google Scholar
• Batus M, Waheed S, Ruby C, Petersen L, Bines SD, Kaufman HL. Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol. 2013;14(3):179–94.
   PubMed Web of Science ®Google Scholar
• Malas S, Harrasser M, Lacy KE, Karagiannis SN. Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncology Reports. 2014;32(3):875–86. Sep
   PubMed Web of Science ®Google Scholar
• Cacan E, Spring AM, Kumari A, Greer SF, Garnett-Benson C. Combination treatment with sublethal ionizing radiation and the proteasome inhibitor, bortezomib, enhances death-receptor mediated apoptosis and anti-tumor immune attack. IJMS. 2015;16(12):30405–21.
   Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Letters. 2018;419:210210–21. Apr
   Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–701.
   PubMed Web of Science ®Google Scholar
• Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5(3):194–203. Sep
   PubMed Web of Science ®Google Scholar
• Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Rébé C, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PloS One. 2013;8(6):e65181.
   PubMed Web of Science ®Google Scholar
• Galluzzi L., Vacchelli E., Bravo-San Pedro J-M, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado J-P, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–508.
   PubMed Web of Science ®Google Scholar
• Janicka M, Gubernator J. Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy. Expert Opin Drug Deliv. 2017;14(9):1059–75.
   PubMed Web of Science ®Google Scholar
• Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immunogenic cell death in human cancer. Front Immunol. 2014;4:503. 6
   PubMed Web of Science ®Google Scholar
• van Vliet AR, Martin S, Garg AD, Agostinis P. The PERKs of damage-associated molecular patterns mediating cancer immunogenicity: from sensor to the plasma membrane and beyond. Semin Cancer Biol. 2015;33:74–85. Aug
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget. 2015;6(39):41600–19. Dec 8
   PubMedGoogle Scholar
• Buac D, Shen M, Schmitt S, Rani Kona F, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP. From bortezomib to other inhibitors of the proteasome and beyond. CPD. 2013;19(22):4025–38.
   Google Scholar
• Wang H, Guan F, Chen D, Dou QP, Yang H. An analysis of the safety profile of proteasome inhibitors for treating various cancers. Expert Opin Drug Saf. 2014;13(8):1043–54. Aug
   PubMed Web of Science ®Google Scholar
• Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H, et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Therapeut. 2010;9(6):1842–51. Jun
   PubMed Web of Science ®Google Scholar
• Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017;18(7):929–45. Jul
   PubMed Web of Science ®Google Scholar
• Xu L, Tu Z, Xu G, Wang Y, Pan W, Zhan X, Luo Q, Huang Y, Chen J, Huang A, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep. 2014;9(4):1345–50. Apr
   PubMed Web of Science ®Google Scholar
• Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, et al. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol. 2013;9(10):1477–87. Oct
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2014;88(1):216–25. Sep
   PubMed Web of Science ®Google Scholar
• Liu K. Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer. WJGO. 2010;2(11):399–406. 15
   Google Scholar
• Yaacoub K, Pedeux R, Tarte K, Guillaudeux T. Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Lett. 2016;378(2):150–9. 10
   PubMed Web of Science ®Google Scholar
• Cacan E. Combating the epigenome: elucidation of mechanisms underlying chemoresistance and enhancing tumor immunogenicity. Georgia State University, 2015.
   Google Scholar
• Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer. 2011;98(2):E25–31. Feb
   PubMed Web of Science ®Google Scholar
• Cacan E. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017;29(3):173–8.
   PubMed Web of Science ®Google Scholar
• Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471.
   PubMedGoogle Scholar
• Cencini E, Guerrini S, Mazzei MA, Chiappella A, Fabbri A. Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab. J Chemother. 2016;28(5):435–40. Oct
   PubMed Web of Science ®Google Scholar
• Shen Y, Lu L, Xu J, Meng W, Qing Y, Liu Y, Zhang B, Hu H. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Cell Biol Int. 2013;37(10):1114–21. Oct
   PubMed Web of Science ®Google Scholar
• Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, et al. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007;48(10):4706–19. Oct
   PubMed Web of Science ®Google Scholar
• Yerlikaya A, Altikat S, Irmak R, Cavga FZ, Kocacan SA, Boyaci I. Effect of bortezomib in combination with cisplatin and 5fluorouracil on 4T1 breast cancer cells. Mol Med Rep. 2013;8(1):277–81. Jul
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, Coleman M, Leonard JP, Furman RR. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(8):1469–73. Aug
   PubMed Web of Science ®Google Scholar
• Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Therapeut. 2007;6(2):644–54. Feb
   PubMed Web of Science ®Google Scholar
• Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy Na, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014 ;3(9):e955691 Oct
   PubMed Web of Science ®Google Scholar
• Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med. 2016 ;8(328):328ra27. Mar 2
   PubMed Web of Science ®Google Scholar